IMPACTOS EMOCIONAIS, SOCIAIS E ECONÔMICOS DA MIASTENIA GRAVIS
UMA REVISÃO INTEGRATIVA
DOI:
https://doi.org/10.36557/2674-8169.2026v8n10p1959-1992Palavras-chave:
Miastenia gravis, Qualidade de vida, Saúde mental, Impacto social, Impacto econômico, Adesão terapêuticaResumo
Introdução: A miastenia gravis é uma doença neuromuscular autoimune crônica caracterizada por fraqueza muscular flutuante e fatigabilidade, cujas repercussões podem comprometer aspectos emocionais, sociais, funcionais e econômicos. Objetivo: Analisar os impactos psicológicos e socioeconômicos da miastenia gravis e sua influência na qualidade de vida e na adesão terapêutica. Metodologia: Foi realizada uma revisão integrativa da literatura, com síntese narrativa e temática e pergunta de pesquisa estruturada pelo modelo SPIDER. As buscas ocorreram nas bases PubMed e Biblioteca Virtual em Saúde. A seleção envolveu triagem de títulos e resumos e posterior leitura integral, utilizando-se o software Rayyan e as recomendações do PRISMA 2020. Resultados e discussão: Foram identificadas 2.455 referências, das quais 386 eram duplicadas. Após a triagem, 193 estudos foram selecionados para leitura integral e 28 compuseram a síntese final. Os achados evidenciaram ansiedade, depressão, medo da progressão, estresse, fadiga e sofrimento psicológico, além de limitações funcionais, redução da participação social, necessidade de suporte familiar e dificuldades laborais. Também foram observados custos assistenciais, perda de produtividade, afastamentos, redução da jornada de pacientes e cuidadores e aposentadoria precoce. Esses fatores apresentaram-se inter-relacionados e associados ao comprometimento da qualidade de vida e da continuidade terapêutica. Considerações finais: A miastenia gravis apresenta repercussões multidimensionais que ultrapassam as manifestações neuromusculares, indicando a necessidade de assistência integral que contemple saúde mental, suporte social, funcionalidade, participação laboral e condições socioeconômicas.
Downloads
Referências
ALSOP, T. et al. Perspectives of people with myasthenia gravis on physical activity and experience of physical activity advice from health professionals in the Australian context: a qualitative study. Disability and Rehabilitation, v. 47, n. 1, p. 156–163, 2025. DOI: https://doi.org/10.1080/09638288.2024.2338877.
ANDERSON, A. et al. Patient perceptions of disease burden and treatment of myasthenia gravis based on sentiment analysis of digital conversations. Scientific Reports, v. 14, art. 7271, 2024. DOI: https://doi.org/10.1038/s41598-024-57825-1.
BOZOVIC, I. et al. Long-term outcome in patients with myasthenia gravis: one decade longitudinal study. Journal of Neurology, v. 269, n. 4, p. 2039–2045, 2022. DOI: https://doi.org/10.1007/s00415-021-10759-4.
CHOI, S. A.; TOUCHETTE, D. R.; KIM, K. Health care costs and resource utilization among patients with myasthenia gravis in the United States. Journal of Managed Care & Specialty Pharmacy, v. 31, n. 5, p. 472–481, 2025. DOI: https://doi.org/10.18553/jmcp.2025.31.5.472.
CHOU, M. et al. A cross-sectional study of quality of life and body image in myasthenia gravis patients: a novel approach using the Individualized Neuromuscular Quality of Life Questionnaire. Muscle & Nerve, v. 72, n. 5, p. 1091–1099, 2025. DOI: https://doi.org/10.1002/mus.70000.
COOKE, A.; SMITH, D.; BOOTH, A. Beyond PICO: the SPIDER tool for qualitative evidence synthesis. Qualitative Health Research, v. 22, n. 10, p. 1435–1443, 2012. DOI: https://doi.org/10.1177/1049732312452938.
DEWILDE, S. et al. A cost analysis of reductions in work productivity for MG patients and their caregivers by symptom severity. Frontiers in Public Health, v. 13, art. 1538789, 2025. DOI: https://doi.org/10.3389/fpubh.2025.1538789.
DIMMICK, H. L. et al. Longitudinal relationships between free-living activities, fatigue, and symptom severity in myasthenia gravis using cohort and individualized models. Muscle & Nerve, v. 71, n. 1, p. 33–42, 2025. DOI: https://doi.org/10.1002/mus.28282.
GASPARINI, V.; MATTAVELLI, D.; PANTONI, L. Delayed diagnosis of myasthenia gravis caused by concurrent anxiety symptoms. Neurological Sciences, v. 46, n. 9, p. 4691–4693, 2025. DOI: https://doi.org/10.1007/s10072-025-08240-5.
GILHUS, N. E. et al. Myasthenia gravis. Nature Reviews Disease Primers, v. 5, art. 30, 2019. DOI: https://doi.org/10.1038/s41572-019-0079-y.
HUGHES, T. et al. Impact of social determinants of health on individuals living with generalized myasthenia gravis and implications for patient support programs. Frontiers in Public Health, v. 11, art. 1147489, 2023. DOI: https://doi.org/10.3389/fpubh.2023.1147489.
JORDAN, B. et al. Personality factors in patients with myasthenia gravis: a prospective study. Brain and Behavior, v. 13, n. 11, art. e3228, 2023. DOI: https://doi.org/10.1002/brb3.3228.
KHODAKARAMI, F. et al. Factors influencing quality of life in myasthenia gravis patients: results from a cross-sectional study in South of Iran. Brain and Behavior, v. 15, n. 8, art. e70680, 2025. DOI: https://doi.org/10.1002/brb3.70680.
KUMAR, R.; NAYAK, C.; NAGAPPA, M.; RAO, S.; SINHA, S.; TALY, A. B. Sleep in Myasthenia Gravis: A Questionnaire-Based Study. Neurology India, v. 72, n. 4, p. 801–805, 2024. DOI: https://doi.org/10.4103/neurol-india.NI_562_17.
LEHNERER, S. et al. Burden of disease in myasthenia gravis: taking the patient's perspective. Journal of Neurology, v. 269, n. 6, p. 3050–3063, 2022. DOI: https://doi.org/10.1007/s00415-021-10891-1.
LIU, C. et al. Post-traumatic stress disorder symptoms after respiratory insufficiency in patients with myasthenia gravis. Psychology, Health & Medicine, v. 26, n. 2, p. 221–227, 2021. DOI: https://doi.org/10.1080/13548506.2020.1807577.
LUO, S. et al. A cross-sectional study on fear of progression in patients with myasthenia gravis. Scientific Reports, v. 15, art. 26181, 2025. DOI: https://doi.org/10.1038/s41598-025-11806-0.
MENG, D.-D. et al. Factors associated with the disease family burden of caregivers of myasthenia gravis patients in northwestern China: a cross-sectional study. Journal of Clinical Neuroscience, v. 119, p. 70–75, 2024. DOI: https://doi.org/10.1016/j.jocn.2023.11.024.
MOURÃO, A. M. et al. Determinants of quality of life in Brazilian patients with myasthenia gravis. Clinics, v. 71, n. 7, p. 370–374, 2016. DOI: https://doi.org/10.6061/clinics/2016(07)03.
NARAYANASWAMI, P. et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology, v. 96, n. 3, p. 114–122, 2021. DOI: https://doi.org/10.1212/WNL.0000000000011124.
OUZZANI, M.; HAMMADY, H.; FEDOROWICZ, Z.; ELMAGARMID, A. Rayyan—a web and mobile app for systematic reviews. Systematic Reviews, v. 5, art. 210, 2016. DOI: https://doi.org/10.1186/s13643-016-0384-4.
PAGE, M. J. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ, v. 372, art. n71, 2021. DOI: https://doi.org/10.1136/bmj.n71.
PESA, J. et al. Clinical characteristics and impairment of activities of daily living among patients with myasthenia gravis with differing degrees of muscle weakness: a real-world study of patients in the US and five European countries. BMC Neurology, v. 24, art. 385, 2024. DOI: https://doi.org/10.1186/s12883-024-03869-9.
PETERSSON, M. et al. Impact of disease activity on quality of life and EQ-5D-3L score in myasthenia gravis: results from the Swedish MG registry. Journal of Neurology, v. 272, n. 9, art. 562, 2025. DOI: https://doi.org/10.1007/s00415-025-13298-4.
POURSHAHRIAR, H.; KHALILI, B.; SHOKRI, O.; FATEHI, F. The assessment of the perceived stress and the quality of life in the patients with myasthenia gravis: the mediating role of the psychological capital and social support. Current Journal of Neurology, v. 23, n. 2, p. 124–130, 2024. DOI: https://doi.org/10.18502/cjn.v23i2.16841.
RANDALL, M. C. Patient perspectives on myasthenia gravis. Disease-a-Month, v. 71, n. 8, art. 101971, 2025. DOI: https://doi.org/10.1016/j.disamonth.2025.101971.
REYES-LEIVA, D. et al. Persistent symptoms, exacerbations and drug side effects despite treatment in myasthenia gravis. European Journal of Neurology, v. 32, n. 1, art. e16463, 2025. DOI: https://doi.org/10.1111/ene.16463.
RODRIGUEZ, R. D. et al. Mental health experiences and challenges among individuals with myasthenia gravis: insights from patient-centered, qualitative analyses. Advances in Therapy, v. 42, n. 12, p. 6209–6233, 2025. DOI: https://doi.org/10.1007/s12325-025-03399-x.
SACCÀ, F. et al. Refocusing generalized myasthenia gravis: patient burden, disease profiles, and the role of evolving therapy. European Journal of Neurology, v. 31, n. 6, art. e16180, 2024. DOI: https://doi.org/10.1111/ene.16180.
SOUZA, M. T.; SILVA, M. D.; CARVALHO, R. Integrative review: what is it? How to do it? Einstein (São Paulo), v. 8, n. 1, p. 102–106, 2010. DOI: https://doi.org/10.1590/S1679-45082010RW1134.
VITTURI, B. K. et al. Social, professional and neuropsychiatric outcomes in patients with myasthenia gravis. Neurological Sciences, v. 42, n. 1, p. 167–173, 2021. DOI: https://doi.org/10.1007/s10072-020-04528-w.
WANG, B. et al. Beyond the surface: investigating the potential mechanisms of non-motor symptoms in myasthenia gravis. European Journal of Neurology, v. 32, n. 8, art. e70309, 2025. DOI: https://doi.org/10.1111/ene.70309.
WHITTEMORE, R.; KNAFL, K. The integrative review: updated methodology. Journal of Advanced Nursing, v. 52, n. 5, p. 546–553, 2005. DOI: https://doi.org/10.1111/j.1365-2648.2005.03621.x.
WU, W. et al. Comparison of the Quantitative Myasthenia Gravis and Myasthenia Gravis Activity of Daily Living Scores from a clinical practice perspective. Muscle & Nerve, v. 72, n. 5, p. 1100–1107, 2025. DOI: https://doi.org/10.1002/mus.70013.
XU, R. H. et al. Developing the health state classification system for a condition-specific preference-based measure for patients with myasthenia gravis. Disability and Rehabilitation, v. 45, n. 20, p. 3366–3372, 2023. DOI: https://doi.org/10.1080/09638288.2022.2120096.
YODER, K. et al. The economic burden of myasthenia gravis (MG): a survey of affected people and their families. Muscle & Nerve, v. 71, n. 2, p. 244–251, 2025. DOI: https://doi.org/10.1002/mus.28313.
YU, J. et al. Social support and medication adherence among adult myasthenia gravis patients in China: the mediating role of mental health and self-efficacy. Orphanet Journal of Rare Diseases, v. 19, art. 143, 2024. DOI: https://doi.org/10.1186/s13023-024-03145-6.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2026 Kamila Severino Botelho Marques dos Passos, Marco Aurelio Botelho Mendes Silva, Marco Aurelio Gomes Mendonça
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Os autores são detentores dos direitos autorais mediante uma licença CCBY 4.0.
